24/7 Market News Snapshot 05 August, 2025 – Adaptive Biotechnologies Corporation Common Stock (NASDAQ:ADPT)

August 5, 2025

DENVER, Colo., 05 August, 2025 (www.247marketnews.com) – (NASDAQ:ADPT) are discussed in this article.
Adaptive Biotechnologies Corporation has opened today with a notable trading price of $11.00, reflecting an impressive bullish shift of approximately 10.91%. As the stock currently trades at $12.10, it demonstrates a positive sentiment in the market alongside a substantial trading volume of 3.44 million shares, indicating heightened investor interest. Analysts suggest that key resistance levels may be found around $12.50, while support could be established near $11.00. These developments underscore growing optimism in the biotechnology sector, particularly in adaptive immune system therapies.

The company has also recently reported robust financial results for the quarter ending June 30, 2025, achieving revenues of $58.9 million, which represents a remarkable year-over-year increase of 36%. A major highlight was the Minimal Residual Disease (MRD) segment, contributing $49.9 million in revenue and achieving an adjusted EBITDA of $1.9 million, marking a significant 42% growth from the same quarter last year. The clonoSEQ test’s volume surged by 37%, showcasing a strong demand and operational efficiency.

Chad Robins, CEO and co-founder of Adaptive Biotechnologies, emphasized the company’s commitment to advancing the MRD segment and expressed enthusiasm for raising revenue guidance for this business area. The integration of the clonoSEQ test into Flatiron’s OncoEMR platform enhances accessibility for both physicians and patients, while the deployment of the NovaSeq X Plus for clinical sequencing reaffirms the firm’s leadership in precision medicine.

Looking forward, Adaptive Biotechnologies has updated its projection for 2025 full-year MRD revenue to the range of $190 million to $200 million, indicating an anticipated growth of 31% to 37%. The company is also committed to optimizing financial strategies by reducing total cash burn to between $45 million and $55 million, signaling a disciplined focus on future innovation and patient care initiatives.

Related news for (ADPT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.